New approaches to treat myeloid neoplasms

David Steensma, MD of the Dana-Faber Cancer Institute, Boston, MA discusses the arrival of a new splicing modulator called H3B-8800 into clinic later this year for patients with myeloid neoplasms. Dr Steensma discusses how a subset of patients with IDH mutations are potentially eligible for treatment with the IDH inhibitors AG-221, AG-120 and AG-811. Further, Dr Steensma discusses developments for some biomarkers signatures, such as the super enhancer signature, that may predict response to retinoid therapy and bromodomain inhibitor therapy.
Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland.

Share this video